Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Invested Capital (2020 - 2022)

Atea Pharmaceuticals has reported Invested Capital over the past 3 years, most recently at $663.2 million for Q3 2022.

  • Quarterly results put Invested Capital at $663.2 million for Q3 2022, up 14.06% from a year ago — trailing twelve months through Sep 2022 was $663.2 million (up 14.06% YoY), and the annual figure for FY2021 was $710.1 million, up 29.62%.
  • Invested Capital for Q3 2022 was $663.2 million at Atea Pharmaceuticals, roughly flat from $660.5 million in the prior quarter.
  • Over the last five years, Invested Capital for AVIR hit a ceiling of $710.1 million in Q4 2021 and a floor of -$76.5 million in Q3 2020.
  • Median Invested Capital over the past 3 years was $586.3 million (2021), compared with a mean of $439.5 million.
  • Biggest five-year swings in Invested Capital: soared 1198.48% in 2021 and later rose 10.47% in 2022.
  • Atea Pharmaceuticals' Invested Capital stood at $547.8 million in 2020, then rose by 29.62% to $710.1 million in 2021, then decreased by 6.6% to $663.2 million in 2022.
  • The last three reported values for Invested Capital were $663.2 million (Q3 2022), $660.5 million (Q2 2022), and $679.9 million (Q1 2022) per Business Quant data.